Biogen, Sage Get FDA Priority Review of Zuranolone

Biogen Inc. and Sage Therapeutics Inc. on Monday said the U.S. Food and Drug Administration granted priority review to the application seeking approval of zuranolone for the treatment of major depressive disorder and postpartum depression.